CEO, President, Evolus
WHY: Nearly $500M-valued company has one of the first neurotoxins that competes with Botox on the commercial market. Previously at Allergan for 14 years as senior VP of Medical Aesthetics division.
RECENT: Initial product Jeuveau, designed to act similarly to Botox but at a lower cost in treating moderate to severe frown lines, got FDA approval in February; had sales kick off in late June.
NOTABLE: Evolus is indirectly involved in a lawsuit with Allergan due to Korean manufacturer of its products, Allergan claims intellectual infringement.
FUN FACTS: Three kids: Sienna, Gavin, and Pierce; favorite book, “Pillars of the Earth.”